Global Blood Therapeutics Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics or view top-rated stocks.

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its quarterly earnings results on Tuesday, May, 4th. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by $0.20. The company earned $39.04 million during the quarter, compared to analysts' expectations of $42.88 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 57.58% and a negative net margin of 167.73%.
View Global Blood Therapeutics' earnings history.

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GBT shares have decreased by 51.0% and is now trading at $26.89.
View which stocks have been most impacted by COVID-19.

15 equities research analysts have issued twelve-month target prices for Global Blood Therapeutics' stock. Their forecasts range from $36.00 to $152.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $80.50 in the next twelve months. This suggests a possible upside of 199.4% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics or view top-rated stocks among Wall Street analysts.

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Global Blood Therapeutics include Evotec (EVTCY), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Legend Biotech (LEGN), I-Mab (IMAB), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Arvinas (ARVN), Schrödinger (SDGR), Reata Pharmaceuticals (RETA), Alkermes (ALKS) and Hypera (HYPMY).
View all of GBT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.56%), Granite Investment Partners LLC (0.16%), Alliancebernstein L.P. (0.12%), New York State Common Retirement Fund (0.08%), Zurcher Kantonalbank Zurich Cantonalbank (0.05%) and Oppenheimer & Co. Inc. (0.03%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics.

GBT stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank , Arizona State Retirement System, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Eric Fink, and Philip A Pizzo.
View insider buying and selling activity for Global Blood Therapeutics or view top insider-selling stocks.

GBT stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Woodward Diversified Capital LLC, Oppenheimer & Co. Inc., Granite Investment Partners LLC, Victory Capital Management Inc., and Cutler Group LP. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eric Fink, and Willie L Jr Brown.
View insider buying and selling activity for Global Blood Therapeutics or or view top insider-buying stocks.

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GBT stock can currently be purchased for approximately $26.89.

Global Blood Therapeutics has a market capitalization of $1.67 billion and generates $123.80 million in revenue each year. The company earns $-247,550,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

Global Blood Therapeutics employs 389 workers across the globe.

The official website for Global Blood Therapeutics is www.gbt.com.

Global Blood Therapeutics is headquartered at 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 741-7700 or via email at [email protected]